Cipla and BioQuiddity Announce EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management

         Cipla and BioQuiddity Announce EU Commercial Partnership for
             OneDose-ReadyfusOR for Post-Surgical Pain Management

  PR Newswire

  MUMBAI, India, July 31, 2014

MUMBAI, India, July 31, 2014 /PRNewswire/ --

Cipla Europe NV ("Cipla") and BioQuiddity Inc. announced today that they
recently entered into a commercial collaboration, covering the territory of
the European Union and certain other European countries, for BioQuiddity's
OneDose ReadyfusOR™ in regional anesthetic applications for post-surgical pain
management. Cipla intends to launch the CE Marked OneDose ReadyfusOR
pre-filled with Ropivacaine under its own label into the German market late
this year. The ready-to-use infusion systems are non-electric, ambulatory, and
should enable seamless transition between sites of care.

 (Logo: http://photos.prnewswire.com/prnh/20140731/700144 )

"Cipla is an excellent strategic partner for BioQuiddity and our pre-filled
ready-to-use post-surgical pain product candidates," said Mr. Joshua Kriesel,
President and CEO . "Cipla's strong commercial record puts them in an
outstanding position to detail the OneDose ReadyfusOR's safety, sterility, and
ease of use value proposition objectives."

"We are thrilled to be BioQuiddity's European commercial partner for the
OneDose ReadyfusOR," said Mr. Frank Pieters, Head Cipla Europe . "Cipla
believes that this post-surgical pain product candidate presents a unique
opportunity to provide an easy to use, well-tolerated, and efficient regional
anesthesia system that could make savings for healthcare providers and
patients."

About Cipla Limited 

Cipla is a global pharmaceutical company which uses cutting edge technology
and innovation to meet the everyday needs of all patients. For more than 70
years, Cipla has emerged as one of the most respected pharmaceutical names in
India as well as across more than 170 countries. Our portfolio includes 2000
products in 65 therapeutic categories with one quality standard globally.
Cipla's turnover in 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty
to provide affordable medicines. Cipla's emphasis on access for patients was
recognized globally for the pioneering role played in HIV/AIDS treatment as
the first pharmaceutical company to provide a triple combination
anti-retroviral (ARV) in Africa at less than one dollar a day and thereby
treating many millions of patients since 2001. 

Cipla's research and development focuses on developing innovative products and
drug delivery systems and has given India and the world many 'firsts', for
instance Triomune. In a tightly regulated environment, the company's
manufacturing facilities have approvals from all the main regulators including
USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one
universal standard both domestically and internationally.

About Cipla Europe NV 

Cipla Europe NV is a 100% subsidiary of Cipla Limited.

About BioQuiddity Inc. 

BioQuiddity is a privately held corporation located in San Francisco,
California. The Company is focused on addressing some of the most pressing
unmet needs in drug infusion today: cost, medication error, sterility,
efficiency, and patient quality of life. BioQuiddity's ultimate objective is
to provide value to the healthcare community by playing a vital role in
containing costs and improving quality via the Company's proprietary unit-dose
infusion systems. The Company is ISO13485 certified. West Pharmaceutical
Services, an existing strategic partner of BioQuiddity's, will be assembling
the OneDose ReadyfusOR.

Media Contact: Charlotte Chunawala Corporate Communications Mob:
+91-7506257377 Email: charlotte.chunawala@cipla.com

Jaisingh Balakrishnan Corporate Communications Mob: +91-9833836185 Email:
jaisingh.krishnan@cipla.com
 
Press spacebar to pause and continue. Press esc to stop.